Table 4

Treatment-emergent serious AEs

Cohort123456789101112131414.115All
Pneumonia 1 (33) [1] 1 (17) [1] 1 (17) [1] 1 (17) [1] 2 (33) [2] 1 (25) [1] 7 (10) [7] 
Pyrexia 1 (33) [1] 1 (33) [1] 1 (17) [1] 1 (17) [1] 1 (17) [1] 5 (7) [5] 
Cellulitis 2 (33) [2] 1 (17) [1] 1 (17) [1] 1 (25) [2] 5 (7) [6] 
Sepsis 2 (50) [3] 1 (25) [1] 1 (17) [1] 4 (6) [5] 
Respiratory failure 1 (25) [1] 1 (17) [1] 1 (17) [1] 3 (4) [3] 
Febrile neutropenia 1 (17) [1] 1 (17) [1] 2 (3) [2] 
Nausea 1 (17) [1] 1 (25) [1] 2 (3) [2] 
Multiorgan failure 1 (17) [1] 1 (17) [1] 2 (3) [2] 
Urinary tract infection 1 (17) [1] 1 (17) [1] 2 (3) [2] 
Cohort123456789101112131414.115All
Pneumonia 1 (33) [1] 1 (17) [1] 1 (17) [1] 1 (17) [1] 2 (33) [2] 1 (25) [1] 7 (10) [7] 
Pyrexia 1 (33) [1] 1 (33) [1] 1 (17) [1] 1 (17) [1] 1 (17) [1] 5 (7) [5] 
Cellulitis 2 (33) [2] 1 (17) [1] 1 (17) [1] 1 (25) [2] 5 (7) [6] 
Sepsis 2 (50) [3] 1 (25) [1] 1 (17) [1] 4 (6) [5] 
Respiratory failure 1 (25) [1] 1 (17) [1] 1 (17) [1] 3 (4) [3] 
Febrile neutropenia 1 (17) [1] 1 (17) [1] 2 (3) [2] 
Nausea 1 (17) [1] 1 (25) [1] 2 (3) [2] 
Multiorgan failure 1 (17) [1] 1 (17) [1] 2 (3) [2] 
Urinary tract infection 1 (17) [1] 1 (17) [1] 2 (3) [2] 

Data are reported as number of patients reporting TEAEs (percentage of patients reporting TEAEs) [number of TEAEs].

or Create an Account

Close Modal
Close Modal